ALSO NOTED: Wyeth releases Tygacil data; Eurand inks deal with GSK; and much more...

> Wyeth has released data from a Phase III trial of Tygacil that shows a statistically similar ability to treat community acquired pneumonia as an existing therapy. Tygacil cured 89.7 percent of patients compared to 86.3 percent for levofloxacin. One infectious disease expert says that new therapies for CAP are needed as antibiotic-resistant strains emerge. Report [1]

> Eurand has inked a licensing deal with GlaxoSmithKline to use its tablet technology in the development of a new formulation of an existing GSK drug. Eurand stands to earn up to $42 million in milestone payments. Their goal is to be ready with an FDA application by the end of 2007. Report [2]

> UCB has expanded its licensing deal with Jazz Pharmaceuticals for the narcolepsy drug Xyrem, doubling the number of countries it has marketing rights to and adding an indication for chronic pain characterized by widespread musculoskeletal aches. Xyrem is in Phase III pain studies. Report [3]

> SkyePharma announced positive late-stage results for a reformulated version of Lodotra for rheumatoid arthritis. Report [4]

> Canadian regulators have approved Tysabri [5] for multiple sclerosis. Report [6]

> Keryx Biopharmaceuticals has struck a licensing agreement with Japan's Kyowa Hakko Kogyo to develop Kyowa's mid-stage cancer therapy, UCN-01, in markets outside of Japan. Report [7]

> Nanogen will pocket $20 million from a deal to sell five years of royalties from its MGB technology to Drug Royalty. Report [8]

> Baxter International is touting the latest preliminary data for its experimental H5N1 vaccine. Report [9]

> Shares of Quest Diagnostics were hammered after the company announced the loss of a contract with UnitedHealthcare. Report [10]

> Acorda Therapeutics announced plans to raise $31.5 million in a private placement. The money is earmarked for pipeline development and sales and marketing. Release [11]

> Schering and Biogen Idec have launched a late-stage trial of their lymphoma drug, Zevalin. Report [12]

> Dynavax Technologies is raising $27 million in a private offering. Report [13]

> Isotechnika says its immunosuppressive therapy ISA247 has won a European patent. Report [14]

And Finally… After seizing more than 40,000 packages of prescription drugs bound for the U.S., Customs says it will stop its program of confiscating the drugs. Article [15]